JP2019515027A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515027A5
JP2019515027A5 JP2019505138A JP2019505138A JP2019515027A5 JP 2019515027 A5 JP2019515027 A5 JP 2019515027A5 JP 2019505138 A JP2019505138 A JP 2019505138A JP 2019505138 A JP2019505138 A JP 2019505138A JP 2019515027 A5 JP2019515027 A5 JP 2019515027A5
Authority
JP
Japan
Prior art keywords
binding fragment
antigen
hvegf
hvegf antigen
glycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019505138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515027A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027650 external-priority patent/WO2017181021A1/en
Publication of JP2019515027A publication Critical patent/JP2019515027A/ja
Publication of JP2019515027A5 publication Critical patent/JP2019515027A5/ja
Priority to JP2022108815A priority Critical patent/JP2022153418A/ja
Priority to JP2024152809A priority patent/JP2025000642A/ja
Pending legal-status Critical Current

Links

JP2019505138A 2016-04-15 2017-04-14 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療 Pending JP2019515027A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022108815A JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2024152809A JP2025000642A (ja) 2016-04-15 2024-09-05 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662323285P 2016-04-15 2016-04-15
US62/323,285 2016-04-15
US201762442802P 2017-01-05 2017-01-05
US62/442,802 2017-01-05
US201762450438P 2017-01-25 2017-01-25
US62/450,438 2017-01-25
US201762460428P 2017-02-17 2017-02-17
US62/460,428 2017-02-17
PCT/US2017/027650 WO2017181021A1 (en) 2016-04-15 2017-04-14 Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022108815A Division JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Publications (2)

Publication Number Publication Date
JP2019515027A JP2019515027A (ja) 2019-06-06
JP2019515027A5 true JP2019515027A5 (https=) 2020-05-28

Family

ID=60041925

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019505138A Pending JP2019515027A (ja) 2016-04-15 2017-04-14 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2022108815A Pending JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2024152809A Pending JP2025000642A (ja) 2016-04-15 2024-09-05 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022108815A Pending JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2024152809A Pending JP2025000642A (ja) 2016-04-15 2024-09-05 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Country Status (9)

Country Link
US (3) US20190127455A1 (https=)
EP (1) EP3442577A4 (https=)
JP (3) JP2019515027A (https=)
KR (2) KR20240005973A (https=)
AU (2) AU2017250797A1 (https=)
CA (1) CA3019665A1 (https=)
IL (1) IL262277A (https=)
SG (2) SG10202008378UA (https=)
WO (1) WO2017181021A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
EP3687464A4 (en) * 2017-09-27 2021-09-29 REGENXBIO Inc. TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST-TRANSLATION MODIFIED ANTI-VEGF FAB
EP3727468A4 (en) * 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
BR112020025268A2 (pt) * 2018-06-28 2021-03-09 The University Of North Carolina At Chapel Hill Cassetes de expressão e genes cln5 otimizados e seu uso
EP4063510A1 (en) * 2018-11-07 2022-09-28 Akouos, Inc. Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
WO2020206098A1 (en) * 2019-04-03 2020-10-08 Regenxbio Inc. Gene therapy for eye pathologies
WO2020219868A1 (en) * 2019-04-24 2020-10-29 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
EP4017523A4 (en) * 2019-08-22 2024-01-17 The Regents Of The University Of California UBE3A FOR THE TREATMENT OF ANGELMAN SYNDROME
CN114502197A (zh) * 2019-08-26 2022-05-13 再生生物股份有限公司 用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变
WO2021071835A1 (en) 2019-10-07 2021-04-15 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113952474A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CA3198368A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Formulations for suprachoroidal administration such as formulations with aggregate formation
CA3198372A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Formulations for suprachoroidal administration such as high viscosity formulations
KR20230106598A (ko) 2020-10-07 2023-07-13 리젠엑스바이오 인크. 겔 제형과 같은 맥락막위 투여용 제형
AU2021358781A1 (en) 2020-10-07 2023-05-18 Tern Therapeutics, Llc Gene therapy for ocular manifestations of cln2 disease
CA3195967A1 (en) * 2020-10-28 2022-05-05 Xu Wang Vectorized anti-tnf-? antibodies for ocular indications
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
CN116917491A (zh) * 2020-12-18 2023-10-20 Ac免疫有限公司 抗体递送
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
JP2024513205A (ja) * 2021-03-31 2024-03-22 ウーシー バイオロジクス アイルランド リミテッド 二重特異性抗pd-l1/vegf抗体およびその使用
CA3245921A1 (en) * 2022-03-17 2023-09-21 Adverum Biotechnologies, Inc. Antibody Cassettes of Constituent 3 Anti-Complement, Vectorization and Therapeutic Application
TW202345913A (zh) 2022-04-06 2023-12-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如凝膠調配物
US20260034243A1 (en) 2022-04-06 2026-02-05 Regenxbio Inc. Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
TW202404651A (zh) 2022-04-06 2024-02-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如形成聚集體之調配物
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0014945A (pt) * 1999-10-21 2004-08-31 Monsanto Co Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
CN1461342A (zh) * 2000-07-26 2003-12-10 路德维格癌症研究所 糖基化vegf-b和增加可溶性vegf-b量的方法
EP2443150B1 (en) * 2009-06-17 2015-01-21 AbbVie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
ES2833230T3 (es) * 2014-05-13 2021-06-14 Univ Pennsylvania Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo

Similar Documents

Publication Publication Date Title
JP2019515027A5 (https=)
US20240270848A1 (en) Combination therapies targeting pd-1, tim-3, and lag-3
JP2016504416A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2016188209A5 (https=)
RU2015121755A (ru) Антагонисты ил-6 и их применение
RU2018125515A (ru) Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2018510617A5 (https=)
JP2018506277A5 (https=)
IL276383B2 (en) Treatment of ophthalmologic diseases
JP2018517431A5 (https=)
JP2020514277A5 (https=)
JP2018527919A5 (https=)
HRP20150281T1 (hr) Prevencija i lijeäśenje stanja oka povezanih sa sustavom komplementa
JP2017535257A5 (https=)
RU2015144105A (ru) Антитела к гепсидину и их применения
JP2016094424A5 (https=)
JP2010526028A5 (https=)
JP2015503909A5 (https=)
JP2019530427A5 (https=)
JP2019505527A5 (https=)
JP2019532617A5 (https=)
JP2018512402A5 (https=)
JP2017534645A5 (https=)
JP2018527327A5 (https=)